Kaleido Biosciences to Present Updated Data of KB295 In Ulcerative Colitis at the 2022 Crohn’s and Colitis Congress
21 janv. 2022 11h04 HE
|
Kaleido Biosciences
LEXINGTON, Mass., Jan. 21, 2022 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage biotech company with a differentiated, small-molecule approach to treating inflammatory...
Kaleido Biosciences Announces Expansion of Collaboration with Janssen to Explore Potential of Microbiome Metabolic Therapies (MMT™) to Prevent Childhood-Onset of Atopic, Immune and Metabolic Conditions
06 déc. 2021 07h30 HE
|
Kaleido Biosciences
LEXINGTON, Mass., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage biotech company with a differentiated, small-molecule approach to treating inflammatory...
Kaleido Biosciences to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference
15 nov. 2021 07h30 HE
|
Kaleido Biosciences
LEXINGTON, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage biotech company with a differentiated, small-molecule approach to treating inflammatory...
Kaleido Biosciences to Appoint Dr. Alison Long as Chief Medical Officer
10 nov. 2021 07h30 HE
|
Kaleido Biosciences
LEXINGTON, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage biotech company with a differentiated, small-molecule approach to treating inflammatory...
Kaleido Biosciences Reports Third Quarter 2021 Financial Results
01 nov. 2021 07h30 HE
|
Kaleido Biosciences
--Achieved primary objective of safety and tolerability in clinical study evaluating KB295 in mild-to-moderate ulcerative colitis; meaningful reduction observed in key biomarkers correlated with...
Kaleido Biosciences to Participate in the Jefferies Virtual Next Generation IBD Therapeutics Summit
12 oct. 2021 07h30 HE
|
Kaleido Biosciences
LEXINGTON, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage biotech company with a differentiated, small-molecule approach to treating inflammatory...
Kaleido Biosciences Announces New Clinical and Preclinical Data Supporting Advancement of KB295 to a Phase 2 Clinical Study in Mild-to-Moderate Ulcerative Colitis
05 oct. 2021 07h00 HE
|
Kaleido Biosciences
KB295 reached its primary endpoint demonstrating favorable safety and tolerability profile Reduction in key ulcerative colitis biomarkers correlated with disease activity and inflammation - fecal...
Kaleido Biosciences to Host Virtual R&D Presentation to Discuss Clinical Data and Pipeline Advancement on October 5, 2021
29 sept. 2021 07h30 HE
|
Kaleido Biosciences
Latest data and clinical development plans for KB295 in ulcerative colitis (UC) to be presented Call to feature leading experts in UC and Chronic Obstructive Pulmonary Disease (COPD) Company...
Kaleido Biosciences to Participate in the Morgan Stanley 19th Annual Virtual Global Healthcare Conference
02 sept. 2021 07h30 HE
|
Kaleido Biosciences
LEXINGTON, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the...
Kaleido Biosciences Reports Second Quarter 2021 Financial Results
11 août 2021 07h30 HE
|
Kaleido Biosciences
--On track to report topline data from a clinical study of KB295 in patients with mild-to-moderate ulcerative colitis by end of third quarter-- --Kaleido and the COPD Foundation to collaborate on the...